ATF5 and central nervous system cancer: Median ATF5 mRNA expression for the cohorts was log2 8.36 in IDH1mut gliomas (SD = 0.66), and log2 9.54 in IDH1wt gliomas (SD = 0.80), and lower ATF5 expression was correlated with survival benefits in both IDH1mut and IDH1wt glioblastomas (log rank P < 0.05; Supplementary Fig. S5B).